论文部分内容阅读
目的观察全反式维甲酸(ATRA)联合三氧化二砷(As2O3)治疗初治急性早幼粒细胞白血病(APL)的疗效。方法对应用ATRA和As2O3联合诱导治疗的20例APL患者的完全缓解(CR)率、达CR所需时间和不良反应进行观察,并与单独应用ATRA组30例进行比较。联合用药组治疗方法为ATRA 25mg/(m2.d),0.1%As2O310ml/d直至CR。结果联合用药组与单独应用ATRA组相比,CR率差异无统计学意义(分别为95%、86.7%,均P>0.05);联合用药组获得CR所需的时间短于单独用药组(平均时间分别为24d、45d,均P<0.05),早期死亡率较单独用药组差异无统计学意义(分别为5%、13.3%,均P>0.05);与单独用药组相比,联合用药组的不良反应并未增加。结论联合用药诱导初发APL缓解的疗效优于单用药组,不良反应少,是一种值得推广应用的方案。
Objective To observe the efficacy of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in the treatment of newly diagnosed acute promyelocytic leukemia (APL). Methods The complete remission (CR) rate, the time required for CR and the adverse reactions were observed in 20 APL patients treated with ATRA and As 2 O 3, and compared with 30 cases of ATRA alone. Combination therapy group ATRA 25mg / (m2.d), 0.1% As2O310ml / d until CR. Results There was no significant difference in the CR rate between the combination group and the ATRA alone group (95% and 86.7%, respectively, all P> 0.05). The time required to obtain CR in the combination group was shorter than that in the ATRA group alone (P <0.05). There was no significant difference in the early mortality rate between the two groups (5 and 13.3%, P> 0.05 respectively). Compared with the single drug group, The adverse reaction did not increase. Conclusions The combination therapy can induce the initial APL to relieve the curative effect better than the single drug group, with less adverse reactions, which is worth popularizing and applying.